Litcius/Paper detail

Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease

Xinyi Zhou, Nan Jin, Fei Wang, Baoan Chen

2020Cancer Cell International71 citationsDOIOpen Access PDF

Abstract

It is well acknowledged that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for numerous malignant blood diseases, which has also been applied to autoimmune diseases for more than a decade. Whereas graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a common serious complication, seriously affecting the efficacy of transplantation. Mesenchymal stem cells (MSCs) derived from a wealth of sources can easily isolate and expand with low immunogenicity. MSCs also have paracrine and immune regulatory functions, leading to a broad application prospect in treatment and tissue engineering. This review focuses on immunoregulatory function of MSCs, factors affecting mesenchymal stem cells to exert immunosuppressive effects, clinical application of MSCs in GVHD and researches on MSC-derived extracellular vesicles (EVs). The latest research progress on MSC in related fields is reviewed as well. The relevant literature from PubMed databases is reviewed in this article.

Topics & Concepts

Mesenchymal stem cellMedicineGraft-versus-host diseaseStem cellHematopoietic stem cell transplantationImmunogenicityTransplantationImmunologyParacrine signallingDiseaseImmune systemHaematopoiesisCancer researchBiologyPathologyInternal medicineCell biologyReceptorMesenchymal stem cell researchExtracellular vesicles in diseaseHematopoietic Stem Cell Transplantation
Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease | Litcius